Blood disorders
Haemophagocytic lymphohistiocytosis
噬血细胞性淋巴组织细胞增生症HLH
A group of related disorders marked by increased lymphocytes and histiocytes and by haemophagocytosis. The two main forms are inherited (primary) and acquired (secondary).
Definition adapted from MeSH (US National Library of Medicine)
Listed in China's second national rare-disease catalogue (2023). The catalogue lists the narrower entry “familial haemophagocytic lymphohistiocytosis”. National Health Commission 国卫医政发〔2023〕26号
- hospitals in mainland China
- 66
- cities
- 32
with a paper from 2016–2025 or a registered study
where those hospitals are
Mainland China accounts for 29% of the world's English-language research papers on haemophagocytic lymphohistiocytosis, 2021–2025 (18% in 2016–2020), and 38% of the world's registered trials on it have a site in China.
Research activity in public records, not a rating of care and not medical advice. How the numbers are made
66 hospitals in 32 cities
Order: papers led on haemophagocytic lymphohistiocytosis, 2021–2025, then A–Z. Research activity, not a rating of care.
A hospital is listed when it led at least 2 papers or 1 trial on haemophagocytic lymphohistiocytosis, or was a site in 2 or more trials. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first. Hospitals not listed may also treat it. Definitions
Cities with the most listed hospitals
Each opens haemophagocytic lymphohistiocytosis in that city. 22 more cities are in the menu below.
- 52 papers led
- 31 papers led
- 22 papers ledNo open trial led
- 20 papers led
- 14 papers ledNo open trial led
- 12 papers ledNo open trial led
- 9 papers ledNo open trial led
- 8 papers ledNo open trial led
- 8 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers led
- 7 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers led
- 6 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
No listed hospital matches these filters.
By university or health system 33
Hospitals carrying a university’s name, added together, plus papers that name only the university. Same order as above.
- 89 papers led6 hospitals
- 28 papers led2 hospitals
- 26 papers led6 hospitals
- 25 papers led5 hospitals
- 20 papers led3 hospitals
- 12 papers led3 hospitals
- 10 papers led4 hospitals
- 10 papers led3 hospitals
- 9 papers led3 hospitals
- 9 papers led3 hospitals
- 9 papers led5 hospitals
- 8 papers led5 hospitals
- 5 papers led3 hospitals
- 5 papers led3 hospitals
- 5 papers led1 hospital
- 5 papers led3 hospitals
- 4 papers led5 hospitals
- 4 papers led1 hospital
- 4 papers led2 hospitals
- 4 papers led3 hospitals
- 4 papers led3 hospitals
- 3 papers led1 hospital
- 3 papers led1 hospital
- 3 papers led1 hospital
- 2 papers led1 hospital
- 2 papers led1 hospital
- 2 papers led1 hospital
- 2 papers led2 hospitals
- 2 papers led1 hospital
- 2 papers led2 hospitals
- 2 papers led2 hospitals
- 2 papers led1 hospital
- 0 papers led0 hospitals
open trials on haemophagocytic lymphohistiocytosis in China
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 8 Nov 2026, with at least one listed hospital as lead sponsor or site. 10 of them are led by a listed hospital. Check the registry for the current status. Whether someone can take part is decided by the study team.
Trials registered only in China’s own registry (ChiCTR) are not included. Questions to check before asking about a trial
What the phases mean (US National Cancer Institute)
- RecruitingCombination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)
- Phase
- Phase 1/Phase 2
- Started
- 2026-04
- Registry
- NCT07525466
Age 18 years to Not stated (registered criteria)
Led by Beijing Tongren HospitalBeijing
- RecruitingHemophagocytic Lymphohistiocytosis After Allogeneic Stem Cell Transplantation
- Phase
- Not given
- Started
- 2026-10
- Registry
- NCT07905066
Age 18 years to Not stated (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingA Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
- Phase
- Phase 3
- Started
- 2025-11
- Registry
- NCT07208058
Age 16 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Nanchang, Shanghai, Shenyang, Shijiazhuang, Wuhan, Zhengzhou
- RecruitingZanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma
- Phase
- Phase 4
- Started
- 2025-11
- Registry
- NCT07270835
Age 14 years to 80 years (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingProspective Single-Arm Clinical Trial of GO Regimen for HLH.
- Phase
- Phase 2/Phase 3
- Started
- 2025-06
- Registry
- NCT07339345
Age 14 years to 70 years (registered criteria)
Led by Beijing Friendship HospitalBeijing
- RecruitingLetermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic Lymphohistiocytosis
- Phase
- N/A
- Started
- 2025-10
- Registry
- NCT07488728
Age Not stated to 18 years (registered criteria)
Led by Beijing Children's HospitalBeijing
- RecruitingClinical Study of EBV-TCR-T Cells for EBV-associated Hemophagocytic Lymphohistiocytosis or EBV Infection
- Phase
- Phase 1
- Started
- 2023-08
- Registry
- NCT06135922
Age 1 year to 60 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingSurveillance and Tracking the Outcomes of Chronic Latent EBV Infection
- Phase
- Not given
- Started
- 2019-07
- Registry
- NCT03491605
Age not stated (registered criteria)
Led by Tongji HospitalWuhan
- Not yet recruitingDose-modified Emapalumab and Ruxolitinib (E-Ru) Regimens for Hemophagocytic Lymphohistiocytosis
- Phase
- Phase 2/Phase 3
- Started
- 2025-06
- Registry
- NCT06951971
Age 1 year to 70 years (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- Not yet recruitingEfficacy and Safety of Carrimycin Tablets in HLH Patients With Carbapenem-resistant Infections
- Phase
- N/A
- Started
- 2023-08
- Registry
- NCT05988177
Age 18 years to Not stated (registered criteria)
Led by Beijing Friendship HospitalBeijing
- Not yet recruitingSegmental Resection Combined With DEP Regimen for EBV-HLH Patients With Intestinal Involvement
- Phase
- Not given
- Started
- 2023-12
- Registry
- NCT06131489
Age 18 years to Not stated (registered criteria)
Led by Beijing Friendship HospitalBeijing
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Before contacting a hospital
The same for every disease, so it is kept on one page. Each hospital page also has an enquiry letter in English and Chinese, and a name card to show staff.
- How to startTalk with the treating doctor, prepare the records hospitals ask for, then write to two or three hospitals.
- Questions to check before asking about a trialWhat the registered criteria usually ask about, and what to ask the study team.
- Common questionsInternational patients, costs, trials and visas.
National guideline (China)
- Standards for 10 childhood blood diseases and cancers (2019 edition)National Health Commission 国卫办医函〔2019〕716号, 2019-09-05; children
- Guidelines for the 86 conditions of the second national rare-disease catalogue (2025 edition)National Health Commission 国卫办医政函〔2025〕252号, 2025-07-10
Written for doctors, in Chinese. We link to the official notice only and do not summarise it; it is not medical advice.
Where these numbers come from
Papers
399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025; a hospital led a paper when its first or last author lists it first. Run the PubMed search
Trials
ClinicalTrials.gov records with a listed hospital as lead sponsor or site, as of 8 Nov 2026. ChiCTR is not included. Search ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.